Mylan Wins Approval for Generic Klor-Con

The FDA has cleared Mylan’s generic version of Upsher-Smith’s potassium drug Klor-Con, and the generics firm has already started shipping the product.

Mylan is the first to launch generic Klor-Con (potassium chloride), the company said Aug. 22.

Klor-Con is prescribed for patients with low potassium. The drug generated $135 million in sales in the 12 months ending June 30, Mylan said, citing IMS Health data. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.